Antihypertensive Drug Treatment Decisions Based on Home Blood Pressure Monitoring
Overview
- Phase
- Phase 4
- Intervention
- Not specified
- Conditions
- Essential Hypertension
- Sponsor
- University of Athens
- Enrollment
- 150
- Locations
- 1
- Primary Endpoint
- Intermediate target organ damage (Left Ventricular Hypertrophy, Microalbuminuria, carotid-femoral Pulse Wave Velocity, Central blood pressure)
- Last Updated
- 13 years ago
Overview
Brief Summary
This is a prospective randomized study with two arms: the Conventional and Ambulatory blood pressure monitoring arm and the Home blood pressure monitoring arm. The study will include both previously treated and untreated individuals.
Before randomization and in the end of the study, measurements will be performed using all three blood pressure monitoring methods (Conventional, Ambulatory and Home) as well as assessment of target organ damage (microalbuminuria, electrocardiogram, echocardiogram, carotid-femoral pulse wave velocity and central blood pressure).
The participants will be randomized into one of the two arms. Diagnosis and titration will be decided according to either Conventional and Ambulatory blood pressure measurements or according to Home blood pressure measurements. Subjects will be followed up for one year.
Investigators
George S. Stergiou
Associate Professor of Medicine and Hypertension
University of Athens
Eligibility Criteria
Inclusion Criteria
- •Untreated hypertensive adults
- •Treated hypertensive adults with uncontrolled blood pressure
Exclusion Criteria
- •Stage III Hypertension
- •Secondary Hypertension
- •Cardiovascular or Renal disease
- •Uncontrolled Diabetes
Outcomes
Primary Outcomes
Intermediate target organ damage (Left Ventricular Hypertrophy, Microalbuminuria, carotid-femoral Pulse Wave Velocity, Central blood pressure)
Time Frame: Baseline and 12 months
Secondary Outcomes
- Blood Pressure Control, Cost-Effectiveness(Baseline and 12 months)